RUNX2 and cleidocranial dysplasia 1: Highlighting the therapeutic implications of these findings, in utero antioxidant therapy stabilized RUNX2 and improved bone development in the Runx2+/– haplo-insufficient mouse model of human cleidocranial dysplasia.